Clinical Spotlight from the 2010 Oncology Annual Meeting in CHicago

These Clinical Spotlight interviews, with accompanying eNewsflash and downloadable slides, discuss the topic of targeting angiogenesis in the treatment of ovarian cancer. This is for viewers in the UK and X-US ovarian specialists who were not able to attend or view this data otherwise.

Activity Information

• Start Date: 6/28/2010
• End Date: 6/28/2011
• Title: Clinical Spotlights on Ovarian Cancer

• Location Information
• Filmed at:  ASCO 2010
• City: Chicago
• State / Province: IL
• Country: United States
• URL to Activity: http://primeoncology.org/2010/chicago/cs/cs3_2/index.html

These Clinical Spotlight interviews, with accompanying eNewsflash and downloadable slides, discuss the topic of targeting angiogenesis in the treatment of ovarian cancer with a focus on the following data release:

#LBA1: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study

The first interview is an expert analysis with Gini Fleming, MD, from the University of Chicago, Illinois in the United States, and Bradley Monk, MD, from the University of California Irvine, Orange, California, United States

The second interview is a supplemental perspective and discussion with Bradley Monk, MD, from the University of California Irvine, Orange, California, United States, and Michael Birrer, MD, PhD, from the Massachusetts General Hospital, Boston, Massachusetts in the United States. 

View the Primary Expert Analysis with Gini Fleming, MD, and Bradley Monk, MD, and access downloadable slides

View the Supplemental Perspectives and Discussion with Bradley Monk, MD, and Michael Birrer, MD, PhD, and access downloadable slides

View eNewsflash

Link to the activity

Images